Monoclonal antibody

Xtalks Announces its Life Science Webinar Calendar for February 2024

Retrieved on: 
Thursday, February 1, 2024
Viral vector, Biomarker, IRT, Robert Williams (robot fatality), Food, Temperature, Skin, Spray drying, Use, Monoclonal antibody, Drug discovery, Metabolism, Automation, Superior, Series, Pharmaceutical industry, Molality, Medical imaging

TORONTO, Feb. 1, 2024 /PRNewswire-PRWeb/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!

Key Points: 
  • Upcoming free, educational webinars from Xtalks will feature topics on biomarkers, clinical trials, drug discovery & development, food, fundamental research, laboratory technology, patient recruitment & retention, pharmaceutical, pharma manufacturing & supply chain and pharmaceutical regulation
    TORONTO, Feb. 1, 2024 /PRNewswire-PRWeb/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries.
  • Access to all webinars is free, so be sure to register today to save your place!
  • Participate in the discussion and stay relevant in your field!
  • Visit http://www.xtalks.com to see our upcoming webinars:
    February 15 - Case Study: EEG Digital Biomarkers in Neuropsychiatric Clinical Studies
    February 15 - Streamlining IRT in Clinical Trials: Simplify, Optimise, Succeed
    February 22 - Endpoint Protection in Rare Disease Trials: Safeguarding Data Integrity for Reliable Outcomes
    February 22 - Responsibly Advancing the Use of AI in Clinical Trials: Current Landscape, Common Misconceptions and Future Opportunities
    February 5 - Unlocking Superior R&D Results: Mastering the FSP Model
    February 14 - Explore the Missing Links of Beauty, Skin, Hair and Joint Wellness
    February 21 - Metabolic Health Trends: The Future of Balanced Wellness
    February 8 - Optimizing Monoclonal Antibody Production: Temperature and Osmolality's Impact
    February 12 and 13 - Electrostatic Spray Drying: A Drying Alternative for Thermosensitive Products (2-Part Series)
    February 27 - Upstream Bioprocessing: DoE Optimization for CHO Cell Cultures
    February 5 - Trial Recruitment Optimization: 5 Reasons Why the Right People Aren't Joining Your Trials
    February 7 - Viral Vector Manufacturing Success Stories: Onboarding to GMP Production
    February 20 - Warehouse Automation Within the Pharmaceutical Industry: Logistics from Dock to Dock

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Retrieved on: 
Wednesday, January 24, 2024
Research, Infectious Diseases, Neurology, Cardiology, Biotechnology, Managed Care, Pharmaceutical, Health, Science, Oncology, Hook effect, DSM-IV codes, Therapy, Monoclonal antibody, Merck Group, ADC, TCR, TRACON, HKEX, Partnership, Infection, IND, Neurocrine, Medication, Antibody, Protein, PCC, Multinational corporation, Hansoh Pharmaceutical, Vaccine

RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.

Key Points: 
  • RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.
  • The RenBiologics logo features an antibody with human-centric design elements, highlighting Biocytogen's expertise in discovering fully human antibodies; the encircled design underscores the company’s dedication to becoming a global resource of fully human antibodies to expedite the development of novel antibody-based therapeutics.
  • Biocytogen’s fully human antibody sequences were generated by proprietary RenMice strains, each engineered to lack a certain drug target gene.
  • RenMice-derived fully human antibodies can be developed into novel therapies to treat numerous cancers, inflammatory and autoimmune diseases, infectious diseases, metabolic diseases, cardiovascular diseases, and neurological diseases.

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Retrieved on: 
Tuesday, January 23, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Hook effect, DSM-IV codes, Therapy, Monoclonal antibody, Merck Group, ADC, TCR, Multimedia, TRACON, HKEX, Partnership, Infection, IND, Neurocrine, Medication, Antibody, Protein, PCC, Multinational corporation, Hansoh Pharmaceutical, Vaccine

RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.

Key Points: 
  • RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.
  • The RenBiologics logo features an antibody with human-centric design elements, highlighting Biocytogen's expertise in discovering fully human antibodies; the encircled design underscores the company’s dedication to becoming a global resource of fully human antibodies to expedite the development of novel antibody-based therapeutics.
  • RenMice®-derived fully human antibodies can be developed into novel therapies to treat numerous cancers, inflammatory and autoimmune diseases, infectious diseases, metabolic diseases, cardiovascular diseases, and neurological diseases.
  • Biocytogen offers licensing and flexible partnering models for its RenMice fully human antibody/TCR discovery platforms.

Syneos Health Releases 2024 Dealmakers' Intentions Survey

Retrieved on: 
Tuesday, January 9, 2024
Gene, Cell, Acquisition, Research, Federal Reserve, Monoclonal antibody, Cardiovascular disease, Survey, FDA, Cancer

MORRISVILLE, N.C., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, today released its Dealmakers’ Intentions Survey.

Key Points: 
  • MORRISVILLE, N.C., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, today released its Dealmakers’ Intentions Survey.
  • The 2024 Survey indicates cautious optimism for biopharmaceutical dealmaking, driven by forward-looking Federal Reserve guidance on interest rate stability and large pharma’s intention to fill revenue and pipeline gaps.
  • Download the full 2024 Dealmakers’ Intentions Survey.
  • Submit a request to have a Syneos Health Consulting team member present Survey results and implications for your business.

Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap

Retrieved on: 
Monday, January 8, 2024
Monoclonal antibody, Immunotherapy, NPC, Atopic dermatitis, Hepatocellular carcinoma, Shanda, Cervical cancer, PD-1, EGFR, CDE, Anemia, NDA, HCC, Cohort, Death, Bevacizumab, NMPA, Ankylosing spondylitis, Summit, Patient, ADC, NSCLC, Hypercholesterolemia, PCSK9, Pembrolizumab, Pharmaceutical industry

Ivonescimab is expected to become the world's first bispecific drug combining immunotherapy and anti-angiogenesis.

Key Points: 
  • Ivonescimab is expected to become the world's first bispecific drug combining immunotherapy and anti-angiogenesis.
  • Potential initiation of a Phase III clinical trial for manfidokimab (IL-4R) for the treatment of moderate atopic dermatitis.
  • Over the next five years, Akeso has high expectations of launching around 10 internally developed blockbuster drugs, both in China and worldwide, thereby achieving successful commercialization.
  • Akeso has established and continuously advances its integrated and efficient system of discovery, development, production, and sales of its innovative drugs and pipeline candidates.

Global Antibody Therapeutic Market Analysis Forecasts High Growth in Biopharmaceutical Sector, 2024-2033 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 5, 2024
Oncology, Health, Infectious Diseases, General Health, Pharmaceutical, Biotechnology, Monoclonal antibody, Intravenous therapy, Research, Prevalence, Administration, Hook effect, Growth, Therapy, Competitive landscape, Route of administration, Marketing

The "Global Antibody Therapeutic Market: Focus on Format, Disease Area, Route of Administration, End Users, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Antibody Therapeutic Market: Focus on Format, Disease Area, Route of Administration, End Users, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
  • This seminal analysis forecasts a significant expansion period in the biopharmaceutical industry, specifically detailing projected growth through the year 2033.
  • The document thoroughly examines antibody therapeutics, which constitute a critical component in the development of treatment options across various disease areas.
  • The breakdown of the global market is distinctly segmented based on disease areas, formats, routes of administration, end-user demographics, and regions.

Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023

Retrieved on: 
Tuesday, November 14, 2023
Pfizer, Antigen, Associate professor, Immune system, GeoVax, Animal, Immunodeficiency, Biotechnology, Protein, Capsid, MVA, Georgia State University, Patient, Vaccine, Immunization, Dihydrolipoyllysine-residue (2-methylpropanoyl)transferase, Infection, Messenger, COVID-19, Monoclonal antibody, Chronic lymphocytic leukemia, Death, Antibody, Alpha, Doctor of Philosophy, Protein structure, SARS-CoV-2, Cancer, CLL, Inflammation, Pharmaceutical industry, Moderna, Boston, Omicron

ATLANTA, GA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of preclinical vaccine efficacy data for GEO-CM02, a multi-antigen investigational SARS-CoV-2 vaccine. The data were presented during the Vaccines Summit 2023 conference, being held in Boston, MA on November 13-15, 2023. The presentation, titled “MVA-vectored multi-antigen COVID-19 vaccines induce protective immunity against SARS-CoV-2 variants spanning Alpha to Omicron in preclinical animal models,” was delivered by Mukesh Kumar, PhD, Associate Professor, Department of Biology, Georgia State University.

Key Points: 
  • The data were presented during the Vaccines Summit 2023 conference, being held in Boston, MA on November 13-15, 2023.
  • To address this limitation, GeoVax is currently evaluating its dual antigen COVID-19 vaccine, GEO-CM04S1 in three Phase 2 clinical trials.
  • Data highlights from the Vaccine Summit 2023 presentation are as follows:
    The GEO-CM02 vaccine induced immune responses that were efficacious against the original Wuhan strain and BA.1 Omicron variant with a single dose.
  • As a booster vaccine for healthy patients who have previously received the Pfizer or Moderna mRNA vaccine.

Prostate Cancer Therapeutics: Comprehensive PSMA-Targeted Therapy Pipeline Review - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 14, 2023
Health, Oncology, Monoclonal antibody, PSMA, Research, Therapy, Quality of life, Diagnosis, Survival, Prostate cancer, Medical imaging

New research detailing advancements in the pipeline of PSMA-targeted therapies for prostate cancer is now available, highlighting the latest developments in one of the most promising areas of cancer treatment research.

Key Points: 
  • New research detailing advancements in the pipeline of PSMA-targeted therapies for prostate cancer is now available, highlighting the latest developments in one of the most promising areas of cancer treatment research.
  • This new research publication offers valuable insights into therapeutics targeting the Prostate-Specific Membrane Antigen (PSMA), a key protein overexpressed in prostate cancer cells.
  • The focused review on PSMA-targeted therapy encompasses a range of approaches, including antibody-drug conjugates, bispecific antibodies, chimeric antigen receptor T-cells, and targeted radioligand therapy.
  • In the wake of a pressing need for more effective prostate cancer treatments, particularly for metastatic castration-resistant prostate cancer (mCRPC), the review of PSMA-targeted therapy candidates plays a crucial role.

Electra Therapeutics presents first clinical data from ongoing Phase 1b study of ELA026 for treatment of secondary hemophagocytic lymphohistiocytosis (sHLH)

Retrieved on: 
Monday, December 11, 2023
Biotechnology, Health, Oncology, Clinical Trials, Assistant, IL2RA, CRP, Safety, C-reactive protein, Therapy, University, ASH, Disease, Patient, Peripheral T-cell lymphoma, Monoclonal antibody, Trial of the century, Prognosis, ORR, MD, HLH, Cancer, SIRP, Doctor of Philosophy, Biomarker, MD Anderson Cancer Center, Society, Pharmaceutical industry, Vaccine, Nursing

Data from ten sHLH patients in the ongoing Phase 1b clinical study showed favorable safety results and overall response rate (ORR) of 70% in all patients dosed with ELA026.

Key Points: 
  • Data from ten sHLH patients in the ongoing Phase 1b clinical study showed favorable safety results and overall response rate (ORR) of 70% in all patients dosed with ELA026.
  • The majority of enrolled patients were difficult-to-treat, malignancy-associated HLH and displayed poor prognostic clinical and biomarker features at baseline.
  • The Phase 1b study is an ongoing open-label, multi-dose, single-arm, multicenter study designed to evaluate the safety and efficacy of ELA026, assess biomarkers and identify a dose for Phase 2/3 testing (ClinicalTrials.gov identifier: NCT05416307 ).
  • “We are extremely encouraged by the data from the first two cohorts, and we look forward to continuing enrollment for this study as we advance the ELA026 clinical program.”

ChromaTan, Inc. Selected as a BLUE KNIGHT™ Company

Retrieved on: 
Tuesday, November 21, 2023
Research, Clinical Trials, Health Technology, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Safety, Plasma, Acceleration, Chemical engineering, ASPR, NIIMBL, FDA, Ecosystem, BLUE, Messenger, Pennsylvania State University, Chemical substance, Plasmid, NIH, HHS, Development, Bayard, Administration, The Blue Knight, Public, 3D printing, Fine chemical, Monoclonal antibody

ChromaTan, Inc., a bioprocess development company revolutionizing the 123-year-old traditional batch biopurification process through transformational next-generation biomanufacturing solutions, announced today that it has been selected as a BLUE KNIGHT™ company.

Key Points: 
  • ChromaTan, Inc., a bioprocess development company revolutionizing the 123-year-old traditional batch biopurification process through transformational next-generation biomanufacturing solutions, announced today that it has been selected as a BLUE KNIGHT™ company.
  • As a Blue Knight company, ChromaTan will gain access to the global JLABS ecosystem, a premier life science incubator program.
  • "We are excited to join JLABS as a Blue Knight company.
  • "I’m thrilled to see ChromaTan selected as a Blue Knight company.